Crystalogram is a noninvasive, liquid-biopsy method for multi-cancer early detection (MCED).
Bahram G. Kermani, Ph.D., Founder and CEO
Bahram G. Kermani is the Founder and CEO of Crystal Genetics, Inc. He is an expert in the field of genomics, computational biology, and pattern recognition. Prior to starting Crystal Genetics, he held various executive and technical positions at Guardant Health, Complete Genomics, Illumina, and Bell Labs (Lucent). Bahram completed his postdoctoral fellowship at Duke University Medical Center. He received his Ph.D. and M.S. in electrical engineering, and biomedical engineering (minor) from North Carolina State University, and received his B.S. in electronics engineering from Amirkabir University of Technology. Bahram has several publications in the areas of genomics, biomedical engineering, and electrical engineering, and holds in excess of 55 issued patents in the United States, Canada, European Union, Australia, China and Japan.
Bahram G. Kermani, Ph.D., Founder and CEO
Bahram G. Kermani is the Founder and CEO of Crystal Genetics, Inc. He is an expert in the field of genomics, computational biology, and pattern recognition. Prior to starting Crystal Genetics, he held various executive and technical positions at Guardant Health, Complete Genomics, Illumina, and Bell Labs (Lucent). Bahram completed his postdoctoral fellowship at Duke University Medical Center. He received his Ph.D. and M.S. in electrical engineering, and biomedical engineering (minor) from North Carolina State University, and received his B.S. in electronics engineering from Amirkabir University of Technology. Bahram has several publications in the areas of genomics, biomedical engineering, and electrical engineering, and holds in excess of 52 issued patents in the United States, Canada, European Union, Australia, China and Japan.
Mark B. Baudler, Corporate Legal Advisor
Mark Baudler is a partner at Wilson Sonsini Goodrich & Rosati (WSGR). He has been an attorney in the firm's corporate securities practice since 1996. Mark's practice focuses on the representation of technology and growth companies at all stages of their development, from seed-stage start-ups and early-stage public companies to mature public companies. His experience includes structuring, managing, and negotiating mergers and acquisitions transactions, public equity offerings, private placement equity and debt transactions, strategic alliances, spin-outs, recapitalizations, and other corporate reorganizations. Mark regularly advises public and private companies and their management on a broad range of corporate matters, including corporate governance responsibilities, equity incentive plans and arrangements, employment matters, intellectual property issues, regulatory compliance, and commercial transactions. In addition, he frequently counsels entrepreneurs on company formation, equity structures, and negotiations with seed and venture capital investors. He also advises venture capital firms and other institutions investing in technology companies. Mark's clients include companies across a diverse range of industries, including mobile, data storage and cloud computing, software, digital media and entertainment, aviation, energy, consumer products and services, semiconductor, the Internet, SaaS, big data, Fintech, Biotech, and other emerging technologies. Mark hold a J.D. from University of Chicago Law School (1996), and a B.A. from Dartmouth College (1991). Mark is admitted to the State Bar of California.
Mark B. Baudler, Corporate Legal Advisor
Mark Baudler is a partner at Wilson Sonsini Goodrich & Rosati (WSGR). He has been an attorney in the firm's corporate securities practice since 1996. Mark's practice focuses on the representation of technology and growth companies at all stages of their development, from seed-stage start-ups and early-stage public companies to mature public companies. His experience includes structuring, managing, and negotiating mergers and acquisitions transactions, public equity offerings, private placement equity and debt transactions, strategic alliances, spin-outs, recapitalizations, and other corporate reorganizations. Mark regularly advises public and private companies and their management on a broad range of corporate matters, including corporate governance responsibilities, equity incentive plans and arrangements, employment matters, intellectual property issues, regulatory compliance, and commercial transactions. In addition, he frequently counsels entrepreneurs on company formation, equity structures, and negotiations with seed and venture capital investors. He also advises venture capital firms and other institutions investing in technology companies. Mark's clients include companies across a diverse range of industries, including mobile, data storage and cloud computing, software, digital media and entertainment, aviation, energy, consumer products and services, semiconductor, the Internet, SaaS, big data, Fintech, Biotech, and other emerging technologies. Mark hold a J.D. from University of Chicago Law School (1996), and a B.A. from Dartmouth College (1991). Mark is admitted to the State Bar of California.
Mark J. Sutherland, Business Development Advisor
Mark Sutherland is the Founder and Principal of Sutherland Life Sciences LLC, a consulting firm which provides business consulting services to a wide variety of Life Sciences, Genomics, Molecular Diagnostics, Immuno-Oncology and Biotechnology companies. He provides guidance and expertise to early-stage startups seeking funding; helps established companies seeking to grow their commercial footprint; and works with global companies looking at potential corporate and product line acquisition opportunities. Mark brings 30 years of Life Sciences and Genomics business experience to Crystal Genetics. His areas of expertise include Next-Generation Sequencing, Gene Expression and Bioinformatics. He has previously held executive-level roles at world-class life sciences companies including Complete Genomics, Bina Technologies (acquired by Roche), Amersham Biosciences / GE Healthcare, Molecular Dynamics and Applied Biosystems. Mr. Sutherland holds a B.S. in Chemistry (with honors in Biochemistry) from Stanford University.
Mark J. Sutherland, Business Development Advisor
Mark Sutherland is the Founder and Principal of Sutherland Life Sciences LLC, a consulting firm which provides business consulting services to a wide variety of Life Sciences, Genomics, Molecular Diagnostics, Immuno-Oncology and Biotechnology companies. He provides guidance and expertise to early-stage startups seeking funding; helps established companies seeking to grow their commercial footprint; and works with global companies looking at potential corporate and product line acquisition opportunities. Mark brings 30 years of Life Sciences and Genomics business experience to Crystal Genetics. His areas of expertise include Next-Generation Sequencing, Gene Expression and Bioinformatics. He has previously held executive-level roles at world-class life sciences companies including Complete Genomics, Bina Technologies (acquired by Roche), Amersham Biosciences / GE Healthcare, Molecular Dynamics and Applied Biosystems. Mr. Sutherland holds a B.S. in Chemistry (with honors in Biochemistry) from Stanford University.
Arnold Oliphant, Ph.D., Science and Technology Advisor
Arnold Oliphant is the CTO of Omniome, and is responsible for leading the research and development of Omniome’s sequencing technology. Arnold has a varied background in developing DNA technologies and their diagnostic applications. Most recently, as the CSO of Ariosa, he led the development of the Harmony NIPT test. Prior to Ariosa, Arnold was the VP of Scientific Operations at Complete Genomics where he led the teams responsible for developing DNA Nano balls and the CPAL sequencing process that produced the most accurate human genome at the time. Before joining Complete Genomics, Arnold was the VP of Scientific Operations at Illumina where he led the team that developed the Golden Gate genotyping assay and the Infinium genotyping assay, the first highly multiplexed genotyping assay capable of genotyping millions of loci simultaneously, now used by 23andMe. Prior to Illumina, Arnold was the VP of Functional Genomics at Myriad Genetics where he led the development of the BRCA1 and BRCA2 diagnostic DNA sequencing test for the predisposition of breast cancer. Arnold holds a PhD in Genetics from Harvard Medical School and a BA in Genetics from the University of Utah.
Arnold Oliphant, Ph.D., Science and Technology Advisor
Arnold Oliphant is the CTO of Omniome, and is responsible for leading the research and development of Omniome’s sequencing technology. Arnold has a varied background in developing DNA technologies and their diagnostic applications. Most recently, as the CSO of Ariosa, he led the development of the Harmony NIPT test. Prior to Ariosa, Arnold was the VP of Scientific Operations at Complete Genomics where he led the teams responsible for developing DNA Nano balls and the CPAL sequencing process that produced the most accurate human genome at the time. Before joining Complete Genomics, Arnold was the VP of Scientific Operations at Illumina where he led the team that developed the Golden Gate genotyping assay and the Infinium genotyping assay, the first highly multiplexed genotyping assay capable of genotyping millions of loci simultaneously, now used by 23andMe. Prior to Illumina, Arnold was the VP of Functional Genomics at Myriad Genetics where he led the development of the BRCA1 and BRCA2 diagnostic DNA sequencing test for the predisposition of breast cancer. Arnold holds a PhD in Genetics from Harvard Medical School and a BA in Genetics from the University of Utah.
Benson Yeung, Strategy and Investment Advisor
Benson Yeung has over two decades of IT architecture and security related experience, including extensive experience as an integrator and distributor of IT products and services. In 1991, Mr. Yeung founded Triware Networld Systems, a San Francisco Bay Area IT systems integrator; and in 2000, he founded Triware Networld Solutions, Inc., a San Francisco Bay Area solution provider for IT knowledge management. In 2011, Mr. Yeung co-founded Rocket EMS, Inc. – an aggressive new company specializing in Electronic Manufacturing Services for fast growth high technology companies with a heavy focus in the New Product Introduction (NPI). Since 1991, Mr. Yeung has also been working closely with various VC firms and startups in Silicon Valley as an Investor, Visionary, Strategist, Technologist and Board of Advisors, Directors or Trustees. In 2018, Mr. Yeung founded Triware Networld Capital, a Venture Capital and Investment firm. Since 1991, Mr. Yeung has consulted on IT and business related issues to over 350 small, medium, and large organizations. Many of those 350 plus companies went IPO, or got acquired. For more than two decades, Mr. Yeung has spent a significant amount of time in IT security fields including being a forensics investigator, auditor and has a deep understanding of the state of IT security issues and has developed frameworks and best practice methodologies for the field. In recent years, Mr. Yeung also serves as a frequent guest speaker, lecturer, panelist, startup pitch judge and mentor at Stanford University, San Jose State University, National University of Singapore, MIT Club, various startup accelerators and incubators including government sponsored events like Kotra (South Korea), ITRI (Taiwan, China), Danish Innovation Center of Silicon Valley and other conferences in topics of all things IT, IT/Cyber security, AI/ML, IoT, IIoT, startup, entrepreneurship, innovation, business ecosystems and VC-related topics, etc.
Benson Yeung, Strategy and Investment Advisor
Benson Yeung has over two decades of IT architecture and security related experience, including extensive experience as an integrator and distributor of IT products and services. In 1991, Mr. Yeung founded Triware Networld Systems, a San Francisco Bay Area IT systems integrator; and in 2000, he founded Triware Networld Solutions, Inc., a San Francisco Bay Area solution provider for IT knowledge management. In 2011, Mr. Yeung co-founded Rocket EMS, Inc. – an aggressive new company specializing in Electronic Manufacturing Services for fast growth high technology companies with a heavy focus in the New Product Introduction (NPI). Since 1991, Mr. Yeung has also been working closely with various VC firms and startups in Silicon Valley as an Investor, Visionary, Strategist, Technologist and Board of Advisors, Directors or Trustees. In 2018, Mr. Yeung founded Triware Networld Capital, a Venture Capital and Investment firm. Since 1991, Mr. Yeung has consulted on IT and business related issues to over 350 small, medium, and large organizations. Many of those 350 plus companies went IPO, or got acquired. For more than two decades, Mr. Yeung has spent a significant amount of time in IT security fields including being a forensics investigator, auditor and has a deep understanding of the state of IT security issues and has developed frameworks and best practice methodologies for the field. In recent years, Mr. Yeung also serves as a frequent guest speaker, lecturer, panelist, startup pitch judge and mentor at Stanford University, San Jose State University, National University of Singapore, MIT Club, various startup accelerators and incubators including government sponsored events like Kotra (South Korea), ITRI (Taiwan, China), Danish Innovation Center of Silicon Valley and other conferences in topics of all things IT, IT/Cyber security, AI/ML, IoT, IIoT, startup, entrepreneurship, innovation, business ecosystems and VC-related topics, etc.
Pirooz Parvarandeh, Strategy and Industry Relations Advisor
Pirooz Parvarandeh is the Chief Operating Officer at Aquantia (NYSE: AQ). He has more than 30 years of experience in the semiconductor industry. Mr. Parvarandeh was formerly the Group President and the first CTO at Maxim Integrated, where he spent 27 years building leading-edge technology businesses. During his tenure at Maxim Integrated he helped scale the company from 150 employees, when he joined, to more than 8,000 employees and revenue of $2.4B. He held technical and management positions with P&L responsibility for highly profitable business units generating up to $800M per year in revenue. He launched multiple initiatives to enhance innovation at Maxim Integrated and started their Automotive Business Unit, which he grew to well over $100M prior to becoming the CTO in 2009. From 2015 to 2018 Mr. Parvarandeh served in senior advisory and consulting roles across a broad range of technologies including Roche’s DNA sequencing unit, as well as multiple startups in the biotech, semiconductor, software and systems sectors. Pirooz completed his Bachelor of Science and Master of Science degrees in Electrical Engineering at the California Institute of Technology, Pasadena, CA and holds 28 issued and pending patents.
Pirooz Parvarandeh, Strategy and Industry Relations Advisor
Pirooz Parvarandeh is the Chief Operating Officer at Aquantia (NYSE: AQ). He has more than 30 years of experience in the semiconductor industry. Mr. Parvarandeh was formerly the Group President and the first CTO at Maxim Integrated, where he spent 27 years building leading-edge technology businesses. During his tenure at Maxim Integrated he helped scale the company from 150 employees, when he joined, to more than 8,000 employees and revenue of $2.4B. He held technical and management positions with P&L responsibility for highly profitable business units generating up to $800M per year in revenue. He launched multiple initiatives to enhance innovation at Maxim Integrated and started their Automotive Business Unit, which he grew to well over $100M prior to becoming the CTO in 2009. From 2015 to 2018 Mr. Parvarandeh served in senior advisory and consulting roles across a broad range of technologies including Roche’s DNA sequencing unit, as well as multiple startups in the biotech, semiconductor, software and systems sectors. Pirooz completed his Bachelor of Science and Master of Science degrees in Electrical Engineering at the California Institute of Technology, Pasadena, CA and holds 28 issued and pending patents.
Kamran Tahamtanzadeh, Corporate Alliances and Relations Advisor
Kamran Tahamtanzadeh (President & Chief Executive Officer of Inanovate Inc a leading proteomics company developing the world’s first multimodal-multiplexing protein measurement platform for disease diagnostics applications, former CEO of EpiCELONA, LLC and Founding CEO at PrognosDx Health, Inc a pioneering Cancer Epigenetics company), is an internationally recognized business executive with focus on Life Sciences, Molecular Diagnostics, Clinical Diagnostics and Medical Oncology market segments. Kamran specializes in building global partnerships and collaborations between promising companies to foster business and scientific exchange, and marketplace success. Managing and building strategic alliances, finding and matching up resources for involved parties has been an essential formula to his successful career especially in the fields of global distributions, international commerce, genomics, proteomics and epigenetics. He has been able to build a network of highly seasoned business executives and scientists and friends in the USA, Europe, India, Asia and in Latin America to shorten business cycles, improve life cycle management, enhance product design and reduce development time and costs, and accelerate corporate growth and scientific advancement. Kamran holds a B.A. degree in Molecular Genetics from U.C. Berkeley.
Kamran Tahamtanzadeh, Corporate Alliances and Relations Advisor
Kamran Tahamtanzadeh (Chief Executive Officer of EpiCELONA, LLC and Founding CEO at PrognosDx Health, Inc a pioneering Cancer Epigenetics company), is an internationally recognized business executive with focus on Life Sciences, Molecular Diagnostics, Clinical Diagnostics and Medical Oncology market segments. Kamran specializes in building global partnerships and collaborations between promising companies to foster business and scientific exchange, and marketplace success. Managing and building strategic alliances, finding and matching up resources for involved parties has been an essential formula to his successful career especially in the fields of global distributions, international commerce, genomics, proteomics and epigenetics. He has been able to build a network of highly seasoned business executives and scientists and friends in the USA, Europe, India, Asia and in Latin America to shorten business cycle, improve life cycle management, enhancing product design and reducing development time and costs, and accelerate corporate growth and scientific advancement. Kamran holds a B.A. degree in Molecular Genetics from U.C. Berkeley.